Clinical trial Recruiting at 1 site Observational Ages 20 to 55 Women only

AMH and Hormonal Profiles in Women with Breast Cancer

Official title: Anti-Müllerian Hormone in Breast Cancer Clinical Practice

Run by Masaryk Memorial Cancer Institute · NCT07896772 · Data updated 2026-11-12

This study tests AMH and other hormonal markers in women with breast cancer and in healthy controls to see how these levels look in real-world care and whether AMH testing can fit into routine practice.

More Breast Cancer trials

Quick facts

Study typeObservational
Ages20 Years to 55 Years
SexWomen only
Enrollment200 (estimated)
SponsorMasaryk Memorial Cancer Institute
Academic / other
Drugs / interventionschemotherapy
Locations1 site (Brno)
StatusRecruiting
StartedNovember 20, 2025
Main results expectedJune 2027
Study endsDecember 2027
Registry record updatedOctober 27, 2026
Trial IDNCT07896772 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women aged 20-55, including those with breast cancer at any treatment stage or follow-up, and healthy female volunteers willing to provide a blood sample.

Probably not a fit

Breast cancer patients not undergoing routine hormonal testing or those who do not consent to additional data collection may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects AMH, FSH, estradiol, TSH, and fT4 from women aged 20-55, including breast cancer patients at various treatment stages and healthy controls. For breast cancer participants, tests proceed as part of usual care without extra procedures; data are gathered from medical records. Healthy volunteers provide a single blood sample and answer a brief questionnaire. The goal is to describe hormonal profiles and assess the feasibility of incorporating AMH testing into routine clinical practice, with preliminary data to inform future research.

Why it matters

Potential benefit: If feasible, routine AMH testing could help personalize hormonal considerations and ovarian reserve counseling for women with breast cancer.

How similar studies have gone: Prior work in this area suggests it is feasible to collect AMH and related hormones in real-world settings, but this study will provide preliminary data specific to breast cancer populations.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women aged 20-55 years.
* Patients with a diagnosis of breast cancer at any of the specified stages of treatment or follow-up, or healthy female volunteers.
* Blood sampling as part of routine clinical care (breast cancer patients) or willingness to undergo a single blood draw (healthy volunteers).

Exclusion Criteria:

* Inability or unwillingness to participate in the study.

Where it's running

  • Masaryk Memorial Cancer Institute
    Brno, Czechia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.